An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Big drugmaker Novo Nordisk is partnering with a company called Vivani to test a new way of delivering semaglutide: an implant. In plain terms, instead of taking a weekly injection or a pill, this would be a small device placed under the skin that slowly releases the medicine over time. The announcement is about launching tests — it’s not saying the implant is approved or already proven to work. Semaglutide is the active ingredient in drugs people might have heard of like Ozempic and Wegovy. It’s a man-made version of a natural hormone that helps control appetite and blood sugar. In people, it makes you feel fuller and slows how quickly the stomach empties, which can lower food intake and help with weight loss and diabetes control. It’s already widely used as a weekly injection and has a well-studied track record for those uses. The news here is specifically about testing an implant to deliver that same drug. The report doesn’t give study details like how many people will be in the trial, how long the implant would last, or whether the first tests are in humans or still in animals. So we don’t yet know how effective or safe the implant form will be compared with current injections. Historically, implants aim to provide steady dosing and reduce the need for frequent injections, but effectiveness and side effects must be demonstrated in formal trials. Why this could matter: an implant could make semaglutide easier for people who don’t want or can’t manage regular injections. It could help with consistent dosing — that’s important for conditions like type 2 diabetes and obesity where steady medication levels can improve outcomes. For some patients, fewer clinic visits and less daily decision-making about medication could improve adherence (sticking with treatment) and results. There are important caveats. An implant requires a minor procedure to insert and remove, which carries risks like infection, device failure, or local reactions. Long-term safety of a continuously released dose needs careful study. Regulatory approval would be required before it became widely available, and the announcement only says they’ll test it — not that it’s safe, effective, or coming to market. People should not assume this is an option yet or try to seek unproven implants. Bottom line: Novo Nordisk and Vivani are exploring a semaglutide implant that could simplify dosing, but it’s early-stage news and we’ll need rigorous trial results before knowing if it’s safe and works as hoped.
Source: Yahoo Finance